miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I

被引：49

作者：

Song, Bin ^{[1
]}

Ji, Weiping ^{[1
]}

Gu, Shiwei ^{[1
]}

Liu, Anan ^{[1
]}

Jing, Wei ^{[1
]}

Shao, Chenghao ^{[1
]}

Li, Gang ^{[1
]}

Jin, Gang ^{[1
]}

机构：

[1] Second Mil Med Univ, Dept Pancreat Surg, Changhai Hosp, Shanghai 200082, Peoples R China

来源：

FEBS LETTERS | 2014年 / 588卷 / 23期

基金：

上海市自然科学基金;

关键词：

miR-545; Pancreatic ductal adenocarcinoma; RIG-I; Patients survival; Cancer growth; HEPATOCELLULAR-CARCINOMA; MICRORNAS; CANCER; RECOGNITION; SURVIVAL; RNA; ACTIVATION; APOPTOSIS; GENES; CELLS;

D O I：

10.1016/j.febslet.2014.10.004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Pancreatic ductal adenocarcinoma (PDAC) ranks fourth on the list of cancer-related causes of death. Deregulation or dysfunction of miRNAs contribute to cancer development. In this study, we found that low miR-545 level and high RIG-I protein in PDAC tissues were both correlated with low survival rate. MiR-545 up-regulation inhibited PDAC cell lines growth and vice versa. 3'UTR of RIG-I was targeted by miR-545. Thus we concluded that low miR-545 levels in PDAC promote tumor cells growth, and this is associated with reduced survival in PDAC patients. MiR-545 exerts its effects by directly targeting RIG-1. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

引用

页码：4375 / 4381

页数：7

共 50 条

[31] Targeted Nanoparticle Delivery of Bifunctional RIG-I Agonists to Pancreatic Cancer
Zillinger, Thomas
Hartmann, Gunther
MOLECULAR THERAPY, 2019, 27 (03) : 491 - 492
[32] Resolving and Targeting the Mechanobiome of Pancreatic Ductal Adenocarcinoma.
Surcel, A.
Zhu, Q.
Schiffhauer, E.
Anders, R. A.
Robinson, D. N.
MOLECULAR BIOLOGY OF THE CELL, 2015, 26
[33] Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy
Zhang, Yi-Fan
Jiang, Shu-Heng
Hu, Li-Peng
Huang, Pei-Qi
Wang, Xu
Li, Jun
Zhang, Xue-Li
Nie, Hui-Zhen
Zhang, Zhi-Gang
CHINESE CLINICAL ONCOLOGY, 2019, 8 (02)
[34] Targeting macrophages to degrade fibrosis in pancreatic ductal adenocarcinoma
Long, Kristen B.
Luque, Santiago L.
Beatty, Gregory L.
CANCER RESEARCH, 2015, 75
[35] How I Treat Pancreatic Ductal Adenocarcinoma
Tempero, Margaret A.
JOURNAL OF ONCOLOGY PRACTICE, 2008, 4 (01) : 46 - 47
[36] RIG-I-Mediated Antiviral Signaling Is Inhibited in HIV-1 Infection by a Protease-Mediated Sequestration of RIG-I
Solis, Mayra
Nakhaei, Peyman
Jalalirad, Mohammad
Lacoste, Judith
Douville, Renee
Arguello, Meztli
Zhao, Tiejun
Laughrea, Michael
Wainberg, Mark A.
Hiscott, John
JOURNAL OF VIROLOGY, 2011, 85 (03) : 1224 - 1236
[37] Antitumor activities of different RIG-I agonists in a murine model of kidney adenocarcinoma
Gulyas, Dominik
Lorincz, Marta
Jankovics, Istvan
Denes, Bela
Foldi, Dora
Rodgers, Rhiannon
Commins, Katie
Andocs, Gabor
Kovacs, Gabor
CANCER IMMUNOLOGY RESEARCH, 2023, 11 (12)
[38] miR-337 regulates the proliferation and invasion in pancreatic ductal adenocarcinoma by targeting HOXB7
Zhang, Rui
Leng, Hong
Huang, Junwen
Du, Yuwen
Wang, Yuanyuan
Zang, Wenqiao
Chen, Xiaonan
Zhao, Guoqiang
DIAGNOSTIC PATHOLOGY, 2014, 9
[39] miR-337 regulates the proliferation and invasion in pancreatic ductal adenocarcinoma by targeting HOXB7
Rui Zhang
Hong Leng
Junwen Huang
Yuwen Du
Yuanyuan Wang
Wenqiao Zang
Xiaonan Chen
Guoqiang Zhao
Diagnostic Pathology, 9
[40] The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS
Zhao, Wu-Gan
Yu, Shuang-Ni
Lu, Zhao-Hui
Ma, Yi-Hui
Gu, Yu-Mei
Chen, Jie
CARCINOGENESIS, 2010, 31 (10) : 1726 - 1733

← 1 2 3 4 5 →